Fennec Pharmaceuticals Inc.

Equities

FENC

CA31447P1009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
6.7 ^USD	-2.47%		-4.83%	-40.29%

May. 15	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	MT
May. 14	Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024

Fennec Pharmaceuticals Inc. Appoints Khalid Islam as Chairman of the Board of Directors

December 09, 2015 at 07:04 am EST

Fennec Pharmaceuticals Inc. announced the appointment of Khalid Islam, PhD, as Chairman of the Board of Directors. Dr. Islam has served as an independent director of Fennec since April 2014. Dr. Khalid Islam brings over 25 years of pharmaceutical and biotechnology experience including Chairman and CEO of Gentium S.p.A.

Latest news about Fennec Pharmaceuticals Inc.

HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	May. 15	MT
Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue	May. 14	MT
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities	May. 14	MT
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction	May. 14	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	Apr. 23	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	Apr. 19	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	Apr. 17	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	Apr. 05	MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	Apr. 04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	Apr. 03	MT
Wedbush on Fennec's Q4	Mar. 21	MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024	Mar. 21
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	Mar. 21	MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	Mar. 21	MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	Mar. 21	MT
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	Mar. 21	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Wedbush on Fennec's Deal for Pedmarqsi in EU	Mar. 18	MT
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 18	MT
Sector Update: Health Care	Mar. 18	MT
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ	Mar. 18	MT

Chart Fennec Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Fennec Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.7 USD

Average target price

16.83 USD

Spread / Average Target

+151.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FENNEC PHARMACEUTICALS INC.	-40.29%	183M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs